TAIWAN, Oct 15 /Xinhua-PRNewswire/ -- Active pharmaceutical ingredient (API) specialist ScinoPharm reported record revenue and profits for the first nine months of 2007, ended 30 September 2007.
“Our business strategy, which is focused on building a strong portfolio of oncology products and a growing base of global customers, continues to drive record performance,” said Dr. Jo Shen, President and CEO of ScinoPharm. “Other factors, including steadier revenue streams from more commercialized products, and improved margins and reduced costs in manufacturing, also contributed to the company’s strong results.”
ScinoPharm, specializing in cytotoxic and high potent APIs, has grown from a regional to a global API manufacturer with significant market presence in the supply of oncology APIs worldwide.
To acquire new orders, the company has acted swiftly in worldwide regulatory registrations of the drug master file (DMF) for its APIs. ScinoPharm recently completed one additional US DMF registration for its oncology API Topotecan HCl, bringing its total US regulatory registrations to 23 and worldwide registrations to over 240.
About ScinoPharm Taiwan
ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a full spectrum of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. The company currently serves more than 160 customers worldwide. To date, it has over 240 DMF registrations worldwide, 23 of which were filed in the US. For more information, please visit the company’s web site at http://www.scinopharm.com .
Jessie.wang@scinopharm.com.tw
CONTACT: Jessie Wang of ScinoPharm Taiwan, +886-6-505-2888 #2880, or
Jessie.wang@scinopharm.com.tw
Web site: http://www.scinopharm.com/
